scispace - formally typeset
M

Michael B. Sporn

Researcher at Dartmouth College

Publications -  561
Citations -  96644

Michael B. Sporn is an academic researcher from Dartmouth College. The author has contributed to research in topics: Transforming growth factor & Transforming growth factor beta. The author has an hindex of 157, co-authored 559 publications receiving 94605 citations. Previous affiliations of Michael B. Sporn include Cornell University & Reata Pharmaceuticals.

Papers
More filters
Journal Article

Histogenesis of squamous metaplasia and squamous cell carcinoma of the respiratory epithelium in an animal model.

Curtis C. Harris, +3 more
- 01 Mar 1973 - 
Journal ArticleDOI

Transforming growth factors from a human tumor cell: characterization of transforming growth factor beta and identification of high molecular weight transforming growth factor alpha.

Linda L. Dart, +4 more
- 08 Oct 1985 - 
TL;DR: The intracellular TGF-beta from the human tumor cell line was similar in all respects tested to normal human placenta and purified to homogeneity as judged by a single peak after reverse-phase high-performance liquid chromatography and a single band on a sodium dodecyl sulfate-polyacrylamide gel.
Journal ArticleDOI

Dichotomies in cancer research: some suggestions for a new synthesis

Michael B. Sporn
- 01 Jul 2006 - 
TL;DR: The purpose of this article is to elaborate on fundamental dichotomies between traditional and revisionist viewpoints and then to attempt a synthesis of these contrasting perspectives.
Journal ArticleDOI

2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid disrupts microtubule polymerization: a possible mechanism contributing to apoptosis.

Robin D. Couch, +7 more
- 01 Apr 2006 - 
TL;DR: CDDO seems to initiate apoptosis early in M phase, possibly through interactions with a hydrophobic site on β-tubulin, and may also involve a reversible 1,4-addition with a protein sulfhydryl group.
Patent

Synthesis and biological activities of new tricyclic-bis-enones (tbes)

Tadashii Honda, +4 more
TL;DR: In this paper, the tricyclic-bis-enone derivatives (TBEs) were described for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.